| Patent application number | Description | Published |
|---|
| 20090258086 | BIOFILM EXTRACELLULAR POLYSACCHARIDE SOLVATING SYSTEM - The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly on human tissues, but which may also be used on hard or soft non-tissue surfaces to breakdown, and/or remove biofilms. | 10-15-2009 |
| 20100086576 | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING SAME - An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macro-molecular matrix is removed or dislodged from the site. | 04-08-2010 |
| 20110040226 | COLD IONIZING RADIATION STERILIZATION - A hydratable gel-forming polymer may be sterilized by chilling the polymer below ambient temperature and sterilizing the chilled polymer using ionizing radiation (e.g., E-Beam radiation). Doing so may reduce the degradation in physical properties caused by ionizing radiation sterilization of the polymer while at ambient temperature, and may preserve or retain desired hydration or gel-forming characteristics. | 02-17-2011 |
| Patent application number | Description | Published |
|---|
| 20090285897 | REHYDRATABLE THIOLATED POLYSACCHARIDE PARTICLES AND SPONGE - Tissue and other body structures may be protected using a hydrated composition made from free-flowing rehydratable particles or a rehydratable sponge comprising substantially collagen-free dehydrothermally crosslinked thiolated polysaccharide. Rehydration of crosslinked or uncrosslinked polysaccharide particles may be carried out without clumping by dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated particles or sponge may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function. | 11-19-2009 |
| 20090291911 | REHYDRATABLE POLYSACCHARIDE PARTICLES AND SPONGE - Tissue and other body structures may be protected using a hydrated composition made from free-flowing substantially collagen-free rehydratable polysaccharide particles and rehydratable polysaccharide sponges. Rehydration of the particles without clumping may be carried out be dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated composition may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function. | 11-26-2009 |
| 20090291912 | CHITOSAN-CONTAINING PROTECTIVE COMPOSITION - Body tissue and structures may be protected using a fluid containing a mixture of partially crosslinked polysaccharide and a further crosslinker. The mixture desirably is sprayable, forms a fluid protective layer via in situ crosslinking, desirably does not drip or run from a treatment site, and may avoid the use of more rapidly curing but potentially less bioacceptable crosslinkers at the treatment site. | 11-26-2009 |
